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This paper provides a critical appraisal of current economic models evaluating preventions or 
treatments for eczema. 
Only a limited range of eczema interventions have been evaluated using economic decision 
modelling. 
There is scope to improve the quality of economic decision models in the area of eczema. 
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ABSTRACT 
Objective 
To identify and assess the quality of published economic decision-analytic models within atopic 
eczema against best practice guidelines, with the intention of informing future decision-analytic 
models within this condition. 
Methods  
A systematic search of the following online databases was performed: MEDLINE, EMBASE, 
Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled 
Trials, Database of Abstracts of Reviews of Effects, Cochrane Database of Systematic Reviews, NHS 
Economic Evaluation Database, EconLit, Scopus, Health Technology Assessment, Cost-
Effectiveness Analysis Registry and Web of Science. Papers were eligible for inclusion if they 
described a decision-analytic model evaluating both the costs and benefits associated with an 
intervention or prevention for atopic eczema. Data was extracted using a standardised form by two 
independent reviewers, whilst quality was assessed using the model specific Philips criteria. 
Results 
24 models were identified, evaluating either preventions (n=12) or interventions (n=12). 14 reported 
using a Markov modelling approach, 4 utilised decision trees and 1 a discrete event simulation, whilst 
5 did not specify the approach. The majority, 22 studies, reported that the intervention was dominant 
or cost-effective, given the assumptions and analytical perspective taken. Notably the models tended 
to be short-term (16 used a time horizon of one year or less), often providing little justification for the 
limited time horizon chosen. The methodological and reporting quality of the studies was generally 
weak, with only 7 studies fulfilling more than 50% of their applicable Philips criteria.  
Conclusions 
This is the first systematic review of decision models in eczema. Whilst the majority of models 
reported favourable outcomes in terms of the cost-effectiveness of the new intervention, the 
usefulness of these findings for decision making is questionable. In particular, there is considerable 
scope for increasing the range of interventions evaluated, for improving modelling structures and 
reporting quality.  
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Key Points 
This paper is the first to identify and critically appraise current economic models evaluating 
preventions or treatments for eczema. 
Only a limited range of eczema interventions have been evaluated using economic decision 
modelling. 
There is scope to improve the quality of economic decision models in the area of eczema. 
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1 INTRODUCTION 
Atopic eczema, also known as atopic dermatitis and from herein referred to as eczema, is a chronic 
disease characterised by dry, red, itchy skin, which sometimes blisters, weeps or crusts [1]. Eczema 
primarily affects children, with an onset in the first few months of life, although it can also be 
experienced in adulthood [2]. There is currently no cure for eczema, and thus treatments are twofold: 
to control the eczema during periods of remission and to treat the eczema when it becomes 
exacerbated. Individuals with eczema are likely to develop other atopic diseases such as asthma or 
allergic rhinitis, for example, it is estimated that 30% with eczema develop asthma, and 35% develop 
allergic rhinitis [3]. 
Alongside the physical symptoms, sufferers may also experience emotional stress, depression or 
sleep deprivation; resulting in a diminished quality of life [4]. In the United Kingdom, the lifetime 
prevalence of eczema is estimated to be between 12.5 and 20% [5, 6]. The annual personal cost for 
the UK population suffering with eczema, including the costs of purchasing over-the-counter 
preparations, special clothing or laundry detergents, as well as salary losses, has been estimated as 
£297m (price year not stated) [7]. In comparison, the annual cost to the National Health Service is 
estimated to be £125m (price year not stated) [7]. These estimates, paired with the reduced quality of 
life of sufferers, indicate the importance of economic decision making in this area. 
There are currently no published reviews of decision-analytic models pertaining to eczema. Therefore, 
this study aims to systematically identify and review such models, comparing their results and 
evaluating their strengths and limitations relative to the Philips criteria [8], using the three broad 
categories of ‘data’, ‘structure’, and ‘uncertainty and consistency’. In doing so, this study will act as a 
resource for decision makers and interested clinicians, signposting to existing models. It may also 
inform the development of future decision-analytic models within eczema, which may utilise any 
strengths and improve upon any weaknesses identified within this review. 
2 METHODS 
The methods used within this systematic review, have been developed and reported according to the 
suggested methods in “Preferred reporting items for systematic review and meta-analysis protocols 
(PRISMA-P) 2015” [9].  
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2.1 Literature search 
A systematic search was conducted of the following electronic databases, from database inception to 
22nd May 2017: MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature, 
Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, 
Cochrane Database of Systematic Reviews, NHS Economic Evaluation Database, EconLit, Scopus, 
Health Technology Assessment, Cost-Effectiveness Analysis Registry and Web of Science. The 
complete protocol and search strategy is published elsewhere [10], although key search terms 
included: “eczema,” “dermatitis,” “cost,” “QALY” and “econ*”. In addition to the electronic search, the 
reference lists of review papers and eligible studies were inspected, and the authors of any relevant 
conference abstracts were, where possible, contacted. No restriction was made on the publication 
language within the electronic search. 
2.2 Eligibility Criteria 
As the electronic search strategy was used as part of a wider body of work [10], it was designed to 
identify papers reporting primary data on cost and/or outcome (utility or willingness to pay) data on 
eczema. Thus, this systematic review reflects a subset of the results, with the additional eligibility 
criteria that a full economic evaluation be conducted using a decision-analytic modelling approach. In 
this instance, we defined a decision-analytic model to be a mathematical framework that uses data 
from multiple sources to evaluate the long-term costs and benefits of an intervention and its 
comparators, with the aim of informing decision-making [11, 12]. Despite the search strategy not 
being restricted by publication language, only papers in English were considered within the review.  
2.3 Study Selection 
Study selection occurred in two stages and was performed by two independent reviewers. Initially, the 
titles and abstracts of the search results were screened. Following this, the full papers of the 
potentially eligible abstracts were accessed and reviewed, to determine inclusion within the review. 
Where disagreement occurred, a third reviewer was used. 
A flow diagram of the systematic literature search and study selection can be found in Figure 1. 
2.4 Data Extraction 
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Data extraction was carried out with the aim of capturing the main results and identifying key points 
about the decision-analytic model, these included, but were not limited to: type of model used, 
population studied, intervention evaluated, time horizon, and source of clinical and cost data. 
Data was extracted using a standardised form, by two independent reviewers and where 
disagreement occurred, resolution was sought through reviewer discussion. Where any clinical 
questions arose, these were discussed with a consultant dermatologist. Reporting quality was 
assessed using the detailed decision-analytic model specific, Philips Criteria [8]. This criteria is 
commonly used to assess model quality in the existing literature [13-15], and so was deemed the 
most appropriate to be used within this review. 
The data extraction and quality assessment forms can be found in Supplementary Material 1. 
3. RESULTS 
Results are presented using a narrative approach, as it was not appropriate to synthesise the 
findings, due to the heterogeneity of populations, interventions and comparators considered.  
3.1 Description of included models 
A total of 24 models, published between 1997 and 2016, were identified, the general characteristics of 
which are detailed in Table 1. To facilitate comparison, studies are grouped into those evaluating 
preventions and interventions and where possible the same intervention. Also reported are the cost-
effectiveness results using the original price year and currency, as well as an inflated result for a 
common price year (2016) and currency (UK£sterling) using a web-based tool [16]. Where the price 
year was not stated it was assumed, for the purposes of this estimate, to be the year of publication. 
Notably, some of the studies used the same decision model structure [17-20], [21, 22], [23-26] to 
conduct analyses for different countries, whilst the same model was discussed in a HTA monograph 
and within a journal article, albeit narrower in scope [27, 28]. 
Overall, it was judged that nine studies conducted cost-effectiveness analyses [17, 18, 20-23, 29-31], 
11 conducted cost-utility analyses [27, 28, 32-40], three conducted both cost-effectiveness and cost-
utility analyses [24-26], and one carried out a cost-minimisation and cost-effectiveness analysis [19].  
An equal number of studies evaluated preventions and treatments. Of those evaluating preventions 
for eczema, nine [17-20, 23-26, 31], evaluated partially hydrolysed formula milk, given to at risk 
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infants, where ‘at risk’ was defined as having first degree atopic heredity. The comparator for all but 
one of these studies was standard cows’ milk formula, with one study [19], comparing with extensively 
hydrolysed formula milk instead. The remaining three papers considered a mixture of prebiotics [37], 
oral application of bacterial lysate [30] and various prophylactic moisturisers, which included 
sunflower seed oil [40]. In comparison, studies of eczema treatments evaluated a wider range of 
interventions. Four evaluated tacrolimus ointment [21, 22, 34, 36], three considered pimecrolimus 
ointment [27, 32, 33], whilst Garside et al. [28] evaluated both tacrolimus and pimecrolimus. Three 
studies evaluated emollient or barrier preparations [35, 38, 39]. Finally, one Spanish study evaluated 
a topical corticosteroid preparation [29]. Notably no modelling studies were found evaluating a 
broader range of interventions (e.g. education programmes, psychological therapy, or different service 
configurations) beyond medications and formula milk. 
Due to the large number of studies evaluating hydrolysed infant formulas, the most common 
population considered in 12 studies [17-20, 23-26, 30, 31, 37, 40] was infants at risk of developing 
eczema. A further four papers [27, 28, 32, 34] considered subjects of all ages, four [21, 29, 36, 39] 
considered “patients” with eczema without stating the age range, two studies [33, 38], considered 
paediatric patients and two studies [22, 35], looked solely at adults. 
The most common decision-analytic approach was a Markov modelling process, used in 14 studies 
[21-28, 32, 33, 35-38]. Within these, the cycle length ranged from one week [25] to one year [37], 
whilst four studies [21, 26, 32, 33] did not specify the cycle length used. A decision-tree was used in 
four studies [29-31, 40], and only one study was found to use a discrete event simulation model [39]. 
Five papers [17-20, 34], did not explicitly state the methodology used, referring to a “decision-analytic 
model,” although it could be inferred that a Markov modelling approach was used. The majority of 
studies, 14 [17-22, 27, 28, 33-36, 38, 39], used a time horizon spanning a year, and most were 
reportedly conducted using a societal [23, 25, 26, 29, 35, 38, 39] or third party payer [21, 22, 27, 28, 
33, 34, 36, 37] perspective. Other studies report taking multiple perspectives, for example, two studies 
conducted analysis from both third party and societal perspectives [31, 32] and four studies 
considered three different perspectives, the ministry of health, the subject’s family and a societal 
perspective (which combined the two former perspectives) [17-20]. Kiencke et al. failed to report the 
perspective used [30] and Bhanegaonkar et al. reported to use the perspective of “urban populations” 
[24] within their analyses. 
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It was found that 22 studies reported that the intervention was dominant or cost-effective, given the 
assumptions made and the analytical perspective taken. Only two papers [22, 27], found that the 
intervention evaluated was not cost-effective, evaluating tacrolimus and pimecrolimus in comparison 
to topical corticosteroids respectively. Reported incremental cost-effectiveness ranged from $353 [40] 
(equivalent to £246.39 in 2016 prices) per QALY gained, comparing petrolatum cream to usual care 
which in this case was seemingly no treatment, to $40,000 [32] (equivalent to £34,728.01 in 2016 
prices, assuming a price year of 2004) per QALY gained, comparing pimecrolimus ointment to usual 
therapy. A total of seven (29%) studies [17-20, 23-25], were either partially or fully funded, by the 
manufacturer of the evaluated product. 
[INSERT TABLE 1] 
 
3.2 Quality Assessment 
The Philips Criteria [8] consists of 56 items intended to assess the reporting quality of decision 
models across three broad categories: ‘structure’, ‘data’ and ‘uncertainty and consistency’. In this 
review, each item was answered using “yes”, “no”, “partial” or “not applicable”. A response of “yes” 
indicated the question was appropriately answered, “no” indicated it was not answered or not enough 
detail was given, “partial” was used when only some elements of the criteria were satisfied. When an 
item was not relevant to the model, “not applicable” was used. Supplementary Material 2 shows the 
responses given for each of the studies. These broad categories and the item responses, form the 
basis of the following discussion. 
3.2.1 Structure 
It is important when constructing a model to decide which modelling approach to use, as different 
model types are best used in different circumstances [41]. However, a number of papers omitted 
justification for the modelling approach selected and only five papers [22, 25, 27, 28, 37] gave full or 
partial justification regarding the model structure. Of these, Ellis et al. [22] provided a comprehensive 
justification for using a Markov model, stating that “it is able to represent more accurately the cyclic, 
recursive nature of AD. Markov models simulate how patients might experience periods of remission 
and recurrence, and treatment and response,” whilst also citing other published papers that used this 
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modelling approach within other dermatological conditions. Only four papers explicitly discussed the 
implications of using alternative modelling structures [22, 27, 28, 37]. Overall, the selected modelling 
approaches were relatively similar, with the majority of studies using a Markov cohort approach, and 
fewer using decision tree analysis. Interestingly, no studies used a whole disease modelling process 
[42]. Only one study used a discrete event simulation [39], although this was rudimentary, having only 
two health states, eczema and eczema-free, and using data from a single randomised controlled trial. 
The lack of more complex modelling methods, may indicate that a Markov approach is sufficient for 
modelling eczema, without the need for incorporating individual level interaction. Alternatively, it could 
reflect an absence of appropriate data to inform a more complex model, as suggested by Pitt et al., 
“An alternative modelling approach, such as discrete event simulation which could do justice to the 
conditional aspects of treatment might be preferred if such treatment pathway data for eczema were 
available” [27]. In comparison to other similar dermatological conditions, such as psoriasis, there are a 
similarly limited number of modelling approaches used. Findings from a recent systematic review 
within psoriasis found only decision trees and Markov models used [43].  
To evaluate the appropriateness of the modelling approach, the decision problem and objective of the 
evaluation should be described, which was clearly outlined by all but three [29, 39, 40] of the papers. 
In line with the stated objectives, for the majority of papers the costs and outcomes measured were 
also consistent with the perspectives taken. Where a third party perspective was used, primarily the 
costs included were limited to the intervention and wider healthcare costs. By comparison, for studies 
taking a societal perspective, the range of costs included was more varied. Most common was the 
expected productivity losses associated with time off work, or time required to look after children, with 
this cost included in 14 studies [17-20, 23-26, 29, 31, 32, 35, 38, 39]. Less frequently included were 
the transportation costs associated with visiting a physician, included in only six studies [17-20, 23, 
24], as well as the costs of over the counter medications [31, 32], childcare costs [20] and the time 
taken to apply emollients [20]. Of the papers that took a societal perspective, Mertens et al. [31] took 
the most comprehensive view of costs, taking into account productivity losses, the cost of additional 
household expenses such as bed encasings and special diet, as well as any homeopathic treatments 
and over the counter medications required.  
Only one of the studies was thought to have used an inappropriate modelling approach [37], using the 
following four health states: no eczema, eczema, no asthma, asthma, and stating them as “mutually 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
exclusive.” These states are not mutually exclusive and therefore one of the requirements of a Markov 
model is violated [44]. A further nine studies [17-19, 29-32, 34, 40] provided insufficient detail to 
decide if the modelling approach was appropriate. Two studies, using decision trees, [30, 31] had 
relatively long time scales: three and six years respectively, despite decision trees being 
recommended to consider short term events [11].  
In models using a Markov process, the structure usually centred on progression through different 
treatment states, [17-28]. Alternatively, eight studies used disease severity states [32-39]. Of these, 
three studies, [32, 33, 38], used the Investigator’s Global Assessment (IGA) score for eczema [45]. 
The Harmonising Outcome Measures for Eczema (HOME) initiative [46], recommends using Eczema 
Area and Severity Index (EASI) for clinician-reported signs of disease severity, to facilitate 
comparison between trials. Within the review, only two papers referred to the EASI. Abramovits et al. 
[21] calculated percentage improvement using EASI scores at baseline and post treatment defining a 
disease controlled day as >67% improvement, whilst Garside et al. [28]  reported changes in EASI 
score within their effectiveness data. 
Given these different approaches, the strengths and weaknesses of using either treatment or disease 
severity states should be considered, however this evaluation was not found in the current literature. 
We consider that the use of treatment states would facilitate understanding by end users of the 
evaluation process, as the different treatment pathways are clearly displayed. It may also be easier to 
evaluate different pathways using this structure, for example in comparing the introduction of a 
therapy as first-line or second-line treatment, which within a severity state model would be harder to 
achieve. However, as disease severity is not included within treatment states, individuals within the 
same state are assumed to have the same utility and associated costs, despite potentially having 
different eczema severities, unless an adjunct is used. Pitt et al. [27, 28], proposed a model within 
which treatment states are used along with a severity matrix for each state, which states the 
percentage suffering with mild, moderate and severe eczema, allowing for different utilities to be 
assigned accordingly.  
Weinstein et al. [47] suggested that the time horizon for analysis should capture all important benefits 
and consequences. Whilst, eczema is not life limiting, patients can experience periods of remission, 
or may develop the condition for the first time in adulthood [2]. Therefore, whilst a lifelong time horizon 
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may not be necessary, characteristics of the condition indicate the need for an extended time period 
to be modelled. Moreover, the rationale of using a modelling approach is often to go beyond the 
limited time horizons of clinical trials [47]. Therefore, it is surprising that the majority of studies found 
within this review used only a one year time horizon [17-22, 27, 28, 33-36, 38, 39], particularly when 
considering adults: for example, “A shorter time horizon of 1 year was modelled; this duration was 
sufficient to capture the cyclical response and relapse characteristics of eczema,” [27]. In comparison, 
for paediatric populations, the shortest time horizon considered was six months (notably this was a 
decision tree) [40] ranging to 16 years [37], with the majority using a time horizon of six years [23-26, 
30, 31]. 
Of the models where it was applicable, very few papers adequately defined and justified the cycle 
length chosen [27, 36, 38]. More commonly, the cycle length was stated but not justified, with this 
occurring within 10 of the studies [17-20, 23-25, 28, 35, 37]. For the six remaining, the cycle length 
used was either unclear or not explicitly stated, thus reducing the overall transparency of the models. 
For example, a cycle length of one year was used by Lenoir-Wijnkoop et al. [37] evaluating a 
preventative infant formula, with no justification. Given that the cycle length of any model should 
reflect the “minimum interval over which pathology and symptoms is expected to alter,” [8] this is a 
weakness of the current literature.  For the majority of models it was not applicable to apply a half-
cycle correction, given the short cycle lengths chosen [48]. However where it was applicable, very few 
papers discussed using a half-cycle correction or provided justification for why it had not been used. 
Ellis et al. did report using a half cycle correction although the exact cycle length used was not 
explicitly stated [33], whilst Pitt et al. provided justification for not performing a half cycle correction 
[27]. 
3.2.2 Data 
Data sources were consistently underreported, particularly when describing how data was identified, 
which in 13 papers [21-26, 30, 31, 33, 35, 36, 38, 39], was not discussed. Moreover, the quality of the 
data was not assessed in 16 of the papers [20, 21, 23-27, 29, 30, 32, 33, 35-38, 40]. It was also found 
that of the papers which utilised the same model structure for evaluations in different countries [17-20], 
[21, 22], [23-26], very few adaptations were made in terms of the data inputs or model structure. Largely, 
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the only change that was made was to the unit cost sources and currency used, with the clinical data 
inputs remaining unchanged.  
In addition to identified data, a large majority of studies used expert opinion to inform some aspect of 
the decision-analytic model, with only five papers reporting no reliance on expert opinion [30, 33, 36, 
39, 40]. Whilst it is not detrimental to use expert opinion, according to the hierarchy of evidence, as 
outlined by Cooper et al. [49], it is advised that other data sources are consulted before resorting to 
expert opinion. However, by not stating how data were identified, it is unclear whether other sources, 
higher in the hierarchy, were overlooked or if there were simply no other data sources available.  
Of the papers that did use expert opinion to inform parameters, the level of detail as to how opinion was 
elicited was minimal, going against the reporting advice proposed by Leal et al. [50]. In some studies, 
the members of the clinical expert panel were not described, making it difficult to assess whether 
appropriate experts were used, or if their opinions were valid within the population group being studied. 
To demonstrate, Tang et al. [38] considered 12 different countries and relied heavily on expert opinion 
to inform transition probabilities as well as resource use, however, failed to list the members of the 
expert panel and their expertise. Particularly when considering such a wide geographical area, it is 
especially important to provide detail of who the expert panel was, to enhance the transparency of 
assumptions made and to allow judgement of their validity. Three studies provided details on the experts 
used and the methods employed to elicit expert opinion, perhaps due to the sizable reliance on expert 
opinion within the developed models [17-19], although they did not appear to follow formal elicitation 
methods [51]. The most common uses of expert opinion in the studies were to inform treatment 
pathways, approaches and discontinuation rates, as well as estimating levels of resource use across 
different eczema severity levels.   
There were 10 papers [23-25, 30, 31, 33, 34, 36, 39, 40], that used only one source of clinical data for 
treatment effects, only one of which provided justification, stating that only one trial was found in their 
literature search [33]. Of the papers that used more than one source of data, the method of data 
synthesis was consistently underreported, with six papers [26, 27, 32, 35, 37, 38], providing little to no 
detail. In comparison, six studies used a meta-analysis to synthesise treatment effects [17-20, 22, 29], 
ranked as the best source for eliciting clinical effects [49]. Whilst two, [21, 28], were clear in providing 
the calculations and data sources used. 
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Of the 14 studies that conducted a cost-utility analysis, and thus included quality of life as an outcome 
measure, all but one, [34], which utilised unpublished data, provided references to the source of the 
utility weights. One study [40], assumed the same utility values across all of the evaluated moisturisers, 
effectively making the inclusion of utilities redundant. Two studies were also judged to have included 
inappropriate utilities. Coyle & Barbeau [32], considered both an adult and paediatric population, 
however sourced utilities based solely on a paediatric study, without discussing whether this was 
appropriate for an adult population. Similarly, Lenoir-Wijnkoop et al. [37], considered a paediatric 
population, but sourced utilities from a study by Poole et al. [52] which estimated health related utilities 
with the EQ-5D, by mapping responses from adults, using the SF-12. Using adult utilities amongst a 
paediatric population was justified by the authors, stating "there is no evidence that utilities for children 
may be different from those for adults”, but neither does there appear to be any evidence to support the 
use of adult utilities amongst a paediatric population. Despite the other modelling studies using 
appropriate utilities, the method for deriving the utility weights was consistently underreported, and it 
was often necessary to consult referenced papers. Thus, this is one of the areas that future researchers 
could improve in the reporting of their models. One paper that did report this well, by Hjalte et al. [35], 
considered the base case utilities achieved by a Visual Analogue Scale (VAS) and used two different 
methods of derivation, time trade off and standard gamble, within sensitivity analyses. Half of the utility 
studies referenced in some way to Stevens et al. [53]. This study involved 150 members of the general 
population valuing 10 out of 16 possible health states using the standard gamble technique, a disease-
specific preference based instrument later referred to as the ADQoL (Atopic Dermatitis Quality of Life) 
[54]. Interestingly, these utility values have not yet been validated alongside a trial with another validated 
health related quality of life instrument. 
3.2.3 Uncertainty and Consistency 
One of the main incentives for modelling, is the ability to analyse the uncertainty surrounding a result 
[47]. Thus, it is suggested that sensitivity analysis is performed not only to assess the uncertainty in 
parameters used, but also for the methodological, structural and heterogeneity components [8]. 
All papers considered some form of uncertainty within their model, however none appeared to 
address all of the types of uncertainty identified above. Most consistently omitted was the assessment 
of both methodological and structural uncertainties. 
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Assessment of parameter uncertainty was generally well completed, with the majority of papers 
performing at least a one-way sensitivity analysis. Moreover, 11 papers [17-20, 23-28, 34], reported 
performing probabilistic sensitivity analysis (PSA), arguably the most appropriate way to assess 
parameter uncertainty [55]. However, within these, the distributions used were often not justified, 
without which the usefulness of the analysis was reduced. Only seven papers [21, 29-31, 36, 37, 39], 
were judged to have not assessed parameter uncertainty appropriately. This was primarily due to not 
performing sensitivity analyses on all parameters and also not reporting the ranges used.  
Uncertainty associated with heterogeneity, was only assessed within four papers [27, 28, 34, 36], 
which primarily involved looking at the results of the model according to different severities of eczema, 
as well as differences according to subgroups of the population. 
When reporting the internal consistency of models, no study reported testing the mathematical logic of 
the model before use, as recommended by ISPOR [47]. The process of internal validation is key to 
enhancing the trustworthiness of results and ensuring the model is fit for purpose [56]. Similarly, 
between-model validation was only discussed in three papers [25, 26, 39]. For example, 
Bhanegaonkar et al. [25], who presented contradictory results produced from the model and 
discussed why they may have arisen. There was also only one paper by Garside et al. [28] who 
reported calibrating their model against independent data. Other models, stated comparisons were 
not made due to the model being the first of its kind to assess the certain intervention [18, 19], and 
others [22-24, 31, 34], did compare some of the model outputs against existing literature, however not 
decision-analytic models. The remaining 13 studies [17, 20, 21, 27, 29, 30, 32, 33, 35-38, 40] did not 
compare results or offer justification for why this did not occur.  
4 DISCUSSION 
This review has demonstrated the variety of modelling approaches used within eczema, the majority 
being Markov models. Largely, it was found that the rationale for using a modelling approach as 
opposed to any other method of economic evaluation was not well explored, especially given the 
limited time horizon used within many of the studies. Nor was justification for the modelling approach 
selected routinely outlined. As well as this, the associated advantages and disadvantages of using 
either treatment or disease states were not commonly discussed, despite having important 
implications in the modelling process. The treatment state models have the advantage of being more 
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transparent, in that it is easy to see how a patient can progress through the model, however, with the 
development of new treatments and guidelines, it is likely that these models may quickly become 
outdated. Alternatively, in using disease states, it is unlikely that the disease process will drastically 
alter, however, it may be more difficult for the reader to grasp how the interventions being modelled 
affect the transitions, and thus to appreciate the inner workings of the model. This systematic review 
is believed to be the first to review decision-analytic models within eczema. A sizeable number of 
models were identified, comparable to the number found in other reviews in different disease areas, 
for example 18 in Parkinson’s disease [57] and 16 in lower extremity artery disease [58], indicating 
that eczema is certainly not an under researched condition. However, the literature is small in contrast 
to the number of clinical trials available within eczema [59] and the range of interventions evaluated, 
limited in contrast. 
Future modelling studies should consider using routinely collected clinical data to inform parameters 
instead of relying on expert opinion alone. Where this is not feasible, it is important to provide 
sufficient detail on the methods of eliciting expert opinion, including who the experts are and how their 
opinion was elicited. The time horizon of future models should be extended and an effort should be 
made to evaluate a greater range of eczema interventions. There is also no common modelling 
approach currently being implemented, nor is there consensus on the best methodological 
approaches to take. Therefore, there is scope for future research to develop a consensus approach, 
where assumptions and modelling approaches are agreed upon by interested clinicians and expert 
modellers. This has in fact been carried out in other disease areas, such as Rheumatoid Arthritis, with 
the objective to “assist model development and review to inform future policy decisions” [60]. Having 
now identified all published models within eczema, a similar initiative could be implemented. 
Whilst every effort was made to conduct this review in a systematic manner and according to 
published guidelines [9], it is acknowledged that there are some limitations. For example, the search 
strategy only covered published research articles and therefore it is possible that some guidance or 
policy documents relevant to this review, may have been missed. As well as this, despite having two 
reviewers independently extracting data, when assessing the quality of the reporting, the decision as 
to whether criteria were satisfied was subject to individual interpretation of checklist items and the 
relative importance placed on each aspect within it. It is also acknowledged that due to strict journal 
word limits, it is often difficult for authors to include all relevant details of their modelling approach. 
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However, with the increased ability to publish supplementary material, it is likely that in the future this 
difficulty will be reduced.  
The Philips criteria [8] is frequently now used as the standard for assessing model reporting, but it 
was not developed to be used as a checklist and was written with a focus on cumulating all available 
evidence on reporting criteria. Several of the studies in this review were published before the Philips 
criteria [21, 22, 29], thus it may be unfair to assess them based on current standards, given that 
modelling techniques have developed substantially since the original manuscripts were published. 
The Philips criteria have 56 assessment items, so the task of synthesising these for the included 
studies was challenging, meaning only a subset of items have been reported, although the detailed 
assessments can be viewed in Supplementary Material 2.  
5 CONCLUSION 
This review indicates that there are currently no models that satisfy the majority of points within the 
Philips criteria, showing there is scope for improvement. As a result of this review, it can be seen that 
any future model should consider a longer time horizon for both adults and children, in order to ensure 
that all relevant costs and benefits have been considered. 
Data Availability Statement 
The search strategy used to conduct the systematic literature search is published elsewhere [10]. The 
unpopulated data extraction form used within this review, as well as the quality assessment form 
based on the Philips Criteria can be found in Supplementary Material 1. The completed data 
extraction table for all of the studies included within this review can be found in Supplementary 
Material 2.   
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Table 1: Characteristics of included studies. 
Authors, year 
Study 
type 
Intervention / 
Comparator 
Population / 
Country 
Perspective / 
Price Year 
Analytic Approach 
(Time horizon/cycle 
length) 
Primary outcome 
measure 
Sensitivity 
Analysis 
Incremental Cost-Effectiveness results 
Cost-Effectiveness 
adjusted for Price Year 
(2016) and Currency (£) 
STUDIES FOCUSING ON PREVENTION 
Bhanegaonkar 
et al. 2015 
[23] 
CEA Partially hydrolysed 
formula – whey / 
cow’s milk formula 
High risk infants 
/  United States 
Societal / 2013 Markov (6 years / 2 
weeks) 
Reduction in eczema 
risk 
One way and 
probabilistic 
 
Partially hydrolysed formula was 
dominant compared to cow’s milk 
formula. 
Not applicable 
Bhanegaonkar 
et al. 2015 
[24] 
CEA/ 
CUA 
Partially hydrolysed 
formula – whey / 
cow’s milk formula 
High risk infants 
/ Malaysia 
“Urban 
populations” / 
2013 
Markov (6 years / 2 
weeks) 
Reduction in eczema 
risk, QALY (standard 
gamble) 
One way and 
probabilistic 
Partially hydrolysed formula was 
dominant compared to cow’s milk 
formula. 
Not applicable 
Bhanegaonkar 
et al. 2014 
[25] 
CEA/ 
CUA 
Partially hydrolysed 
formula – whey / 
cow’s milk formula 
High risk infants 
/ The 
Philippines 
Societal / 2013 Markov (6 years / 1 
week)  
Reduction in eczema 
risk, QALY (standard 
gamble) 
One way, 
scenario and 
probabilistic 
Partially hydrolysed formula was 
dominant compared to cow’s milk 
formula. 
Not applicable 
Botteman & 
Detzel, 2015 
[26] 
CEA/ 
CUA 
Partially hydrolysed 
formula – whey / 
cow’s milk formula 
High risk infants 
/ Singapore 
Societal / 2013 Markov (6 years / not 
stated)   
Reduction in eczema 
risk, QALY (standard 
gamble) 
One way, 
scenario and 
probabilistic 
Partially hydrolysed formula was 
dominant compared to cow’s milk 
formula. 
Not applicable 
Iskedjian et al. 
2012  [19] 
CMA/CE
A 
Partially hydrolysed 
formula - whey / 
Extensively 
hydrolysed formula 
(EHF-Whey or 
Casein) 
High risk infants 
/  Denmark 
Danish Ministry of 
Health, Family of 
the child, Societal 
/ not stated 
“Decision-analytic 
model” (12 months / 3 
months) 
Avoided cases of 
eczema 
One way and 
probabilistic 
Partially hydrolysed whey based 
formula was found to dominate 
extensively hydrolysed formula from all 
3 perspectives. 
Not applicable 
Table Click here to download Table TABLE 1 - FINAL.docx 
Authors, year 
Study 
type 
Intervention / 
Comparator 
Population / 
Country 
Perspective / 
Price Year 
Analytic Approach 
(Time horizon/cycle 
length) 
Primary outcome 
measure 
Sensitivity 
Analysis 
Incremental Cost-Effectiveness results 
Cost-Effectiveness 
adjusted for Price Year 
(2016) and Currency (£) 
Mertens et al. 
2012 [31] 
CEA Hydrolysed formula 
(partially hydrolysed 
whey, extensively 
hydrolysed whey and 
extensively 
hydrolysed casein) /  
cow’s milk formula 
High risk infants 
/ Germany 
German statutory 
health insurance, 
Societal / not 
stated 
Decision Tree (6 years) Avoided cases of 
eczema 
 
 
 
One way  All 3 hydrolysed formulas were found to 
be dominant from a societal 
perspective, in comparison to regular 
cow’s milk. 
Not applicable 
Iskedjian et al. 
2012 [17] 
CEA Partially hydrolysed 
formula – whey / 
cow’s milk formula 
High risk infants 
/  Switzerland 
Swiss Ministry of 
Health, Family of 
the child, Societal 
/ not stated 
“Decision-analytic 
model” (12 months / 3 
months) 
Avoided cases of 
eczema 
One way and 
probabilistic 
Incremental cost per avoided case of 
eczema was: €982 (Ministry of health 
perspective). From the family and 
societal perspective, partially 
hydrolysed whey formula dominated 
standard cow’s milk formula. 
£511.39 per avoided 
case of eczema. 
[Assumed price year of 
2012] 
Iskedjian et al. 
2010 [18] 
CEA Partially hydrolysed 
formula – whey / 
cow’s milk formula 
High risk infants 
/  France 
French Ministry of 
Health, Family of 
the child, Societal 
/ not stated 
“Decision-analytic 
model” (12 months / 3 
months) 
Avoided cases of 
eczema 
One way and 
probabilistic  
Incremental cost per avoided case of 
eczema was: €1342 from Ministry of 
health perspective and €719 from 
societal perspective. From a family 
perspective, partially hydrolysed whey 
formula was found to dominate 
standard cow’s milk formula. 
Incremental cost per 
avoided case of eczema 
was: £1201.03 (Ministry 
of health perspective) 
and £643.47 (Societal 
perspective) 
[Assumed price year of 
2010] 
Authors, year 
Study 
type 
Intervention / 
Comparator 
Population / 
Country 
Perspective / 
Price Year 
Analytic Approach 
(Time horizon/cycle 
length) 
Primary outcome 
measure 
Sensitivity 
Analysis 
Incremental Cost-Effectiveness results 
Cost-Effectiveness 
adjusted for Price Year 
(2016) and Currency (£) 
Su et al. 2012 
[20] 
CEA Partially hydrolysed 
formula - whey /  
cow’s milk formula 
High risk infants 
/ Australia 
Australian Public 
Health Care, 
Family of the 
child, Societal / 
not stated 
“Decision-analytic 
model” 
(12 months / 6 months) 
Avoided cases of 
eczema 
 
One way and 
probabilistic 
ICERs reported were: AU$496 per case 
avoided (public health care 
perspective), AU$1243 per case avoided 
(societal perspective). From a family 
perspective, the partially hydrolysed 
whey formula dominated standard 
cow’s milk formula.  
Incremental cost per 
avoided case of eczema 
was:  £246.37 (Public 
health care 
perspective) and 
£617.41 (Societal 
perspective) 
[Assumed price year of 
2012] 
Lenoir-
Wijnkoop et 
al. 2012 [37] 
CUA Prebiotics infant 
formula / No 
prebiotics 
High risk infants 
/ The 
Netherlands 
“Health 
insurance” / 2009 
Markov (16 years, 1 
year) 
QALY (Unclear) Not clear 
 
Reported ICER of €472 per QALY gained. 
 
£429.13 per QALY 
gained. 
Kiencke et al. 
2013 [30] 
CEA Prophylactic 
treatment with 
sterile bacterial 
lysate / placebo 
High risk infants 
/ Germany 
Not stated / not 
stated 
Decision Tree (3 years) Avoided cases of 
eczema 
One way Bacterial lysate was found to dominate 
the placebo. 
Not applicable 
Xu et al. 2016 
[40] 
CUA 5 Prophylactic 
Moisturisers and sun 
flower seed oil / 
“Usual Care”  
High risk infants 
/United States 
Not stated / 2016 Decision Tree (6 
months) 
QALY (Standard 
gamble) 
One way Cost effectiveness ranged from 
$353/QALY (Petrolatum) to 
$8386/QALY (Vaniply ointment) 
£246.39/QALY 
(Petrolatum) to 
£5853.43/QALY 
(Vaniply ointment) 
Authors, year 
Study 
type 
Intervention / 
Comparator 
Population / 
Country 
Perspective / 
Price Year 
Analytic Approach 
(Time horizon/cycle 
length) 
Primary outcome 
measure 
Sensitivity 
Analysis 
Incremental Cost-Effectiveness results 
Cost-Effectiveness 
adjusted for Price Year 
(2016) and Currency (£) 
STUDIES FOCUSING ON INTERVENTION 
Healy et al. 
2011 [34] 
CUA Tacrolimus 
maintenance regime 
/ reactive tacrolimus 
treatment 
Adults and 
children / 
United Kingdom 
U.K. National 
Health Service / 
not stated 
“Decision-analytic 
model” (1 year / not 
stated) 
QALY (Standard 
gamble for children, 
unpublished data 
for adults) 
One way and 
probabilistic  
Tacrolimus maintenance treatment was 
dominant compared to tacrolimus 
reactive treatment. 
 
 
 
Not applicable 
Abramovits et 
al. 2003 [21] 
CEA Tacrolimus / 
pimecrolimus 
Eczema 
patients / 
Country not 
stated  
Third party payer 
/ 2002 
Markov (52 weeks / not 
stated) 
Disease controlled 
days (DCD) 
One way  Average cost effectiveness ratio for 
tacrolimus was $7.34 per DCD, $11.34 
per DCD for pimecrolimus. 
£6.68 per DCD, £10.32 
per DCD for 
pimecrolimus. 
Hjelmgren et 
al. 2007  [36] 
CUA Tacrolimus / 
Standard treatment 
(Emollients and 
topical 
corticosteroids) 
Adults /  
Sweden 
Swedish 
healthcare sector 
/ 2004 
Markov (1 year / 3 
weeks) 
QALY (Visual 
Analogue Scale) 
One way  ICERs reported of £12300 (severe 
eczema) and £8300 (moderate eczema) 
per QALY gained using tacrolimus 
ointment compared to standard 
treatment. 
£15896.53 for patients 
with severe eczema, 
and £10726.93 for 
patients with moderate 
eczema, per QALY 
gained. 
Ellis et al. 2003 
[22] 
CEA Tacrolimus /High-
potency topical 
corticosteroids 
Adults / 
Country not 
stated  
Third party payer 
/ not stated 
Markov (1 year / 2 
weeks) 
Disease controlled 
days (DCD) 
One way Average cost effectiveness ratio 
(instead of incremental). 4 week high-
potency topical corticosteroids 
Not applicable 
Authors, year 
Study 
type 
Intervention / 
Comparator 
Population / 
Country 
Perspective / 
Price Year 
Analytic Approach 
(Time horizon/cycle 
length) 
Primary outcome 
measure 
Sensitivity 
Analysis 
Incremental Cost-Effectiveness results 
Cost-Effectiveness 
adjusted for Price Year 
(2016) and Currency (£) 
dominated tacrolimus, whereas 
tacrolimus dominated 2 weekly high-
potency topical corticosteroids. 
Coyle and 
Barbeau, 2004 
[32] 
 
CUA Pimecrolimus/ 
“Usual Therapy” 
Adults and 
children / 
Canada 
Societal and 
health care / not 
stated 
Markov (360 days 
(children), 169 days 
(adults) / not stated) 
QALY (Visual 
Analogue Scale) 
One way Healthcare perspective: ICER value of 
$40000 per QALY (children) and $37000 
(adults). Societal perspective: ICER 
value of $38000 per QALY (children) 
and $35000 (adults). 
 
Incremental cost per 
QALY gained for 
children and adults 
respectively: 
£28465.35, £26330.45 
(Healthcare 
perspective) 
£27042.08, £24907.18 
(Societal perspective) 
 [Assumed price year of 
2004] 
Ellis et al. 2006 
[33] 
CUA Pimecrolimus / 
“Conventional 
Therapy” 
Children (2-17 
years) / Country 
not stated  
Third party payer 
/ 2004 
Markov (1 year / not 
stated) 
QALY (Visual 
Analogue Scale) 
One and Two 
way  
ICER of US$38231 per QALY gained. £33192.16 per QALY 
gained. 
Pitt et al. 2006 
[27] 
CUA Pimecrolimus / 
Topical 
corticosteroids 
Adults and 
children / 
United Kingdom 
U.K. National 
Health Service / 
2003 
Markov (1 year (adults) 
14 years (children) / 1 
month) 
QALY (Standard 
gamble) 
One way and 
probabilistic  
Topical corticosteroids dominated 
pimecrolimus. 
Not applicable 
Authors, year 
Study 
type 
Intervention / 
Comparator 
Population / 
Country 
Perspective / 
Price Year 
Analytic Approach 
(Time horizon/cycle 
length) 
Primary outcome 
measure 
Sensitivity 
Analysis 
Incremental Cost-Effectiveness results 
Cost-Effectiveness 
adjusted for Price Year 
(2016) and Currency (£) 
Garside et al. 
2005 [28] 
CUA Pimecrolimus and 
tacrolimus / Topical 
corticosteroids 
Adults and 
children / 
United Kingdom 
U.K. National 
Health Service / 
2003 
Markov ( 1 year (adult) 
14 years (children) / 4 
weeks) 
QALY (Standard 
gamble) 
One way and 
probabilistic  
(Not all ICERs presented as there were 
approximately 8 models with different 
treatment pathways) 
For pimecrolimus as first line treatment, 
in children, corticosteroids were found 
to dominate. For tacrolimus as first line 
treatment, in children, the ICER value 
was £35,669 per QALY gained. 
£47436.14 per QALY 
gained, for tacrolimus 
as first line treatment. 
Hjalte et al. 
2010 [35] 
CUA Moisturising cream / 
No treatment 
Adults /  
Sweden, 
Denmark, 
Norway and 
Finland 
Societal / 2008 Markov (1 year / 3 
weeks) 
QALY (Visual 
Analogue Scale) 
One way  Reported ICER of €5479 per QALY 
gained for treatment with moisturising 
cream in comparison to no treatment, 
within Sweden, €26908 within 
Denmark, €26118 within Norway, 
€9518 within Finland. 
£4671.43(†) per QALY 
gained, within Sweden, 
£20428.62(†) within 
Denmark, £19163.98(†) 
within Norway, 
£8243.44 within 
Finland. 
Norrlid et al. 
2016 [39] 
CUA Moisturiser 
containing 5% urea / 
Moisturiser with no 
active ingredients 
“Patients with 
AD” / Finland, 
Norway, 
Sweden 
Societal / 2014 “Discrete Event Model” 
(1 year / Not applicable) 
QALY (Not stated) One way The barrier-strengthening moisturiser 
was found to dominate the moisturiser 
with no active ingredients. 
Not applicable 
Authors, year 
Study 
type 
Intervention / 
Comparator 
Population / 
Country 
Perspective / 
Price Year 
Analytic Approach 
(Time horizon/cycle 
length) 
Primary outcome 
measure 
Sensitivity 
Analysis 
Incremental Cost-Effectiveness results 
Cost-Effectiveness 
adjusted for Price Year 
(2016) and Currency (£) 
Tang et al. 
2015 [38]  
CUA Non-steroidal barrier 
cream / regular 
emollient 
Children / Asia 
(12 countries) 
Societal / 2013 Markov (1 year / 22 
days) 
QALY (Multiple 
sources, some Visual 
Analogue Scale, 
others Standard 
gamble) 
One way and 
scenario  
The non-steroidal barrier cream 
dominated regular emollient cream. 
Not applicable 
De Tiedra et 
al. 1997 [29] 
CEA Topical 
prednicarbate 0.25% 
/ fluocortin 0.75% 
Patients with 
“inflammatory 
dermatoses” / 
Spain 
Societal / 1996 Decision tree (not 
stated) 
Patients achieving a 
therapeutic success 
One way "The cost per patient successfully 
treated was Pta 5608 for prednicarbate 
and Pta 8680 for fluocortin."  
£53.56 for 
prednicarbate and 
£82.90 for fluocortin. 
(†) Note: This paper converted results into a common currency, Euros, without providing the exchange rate used. Thus to convert these results into 2016 prices, using UK£Sterling, it was necessary to convert the prices back into the 
original country’s currency, using the average exchange rate for the 2008 price year, sourced from the European central bank, using this value to then inflate and convert to 2016, UK£Sterling, prices, using a web based tool [16]. 
Abbreviations: CEA: Cost-effectiveness analysis, CMA: Cost-minimisation analysis, CUA: Cost-utility analysis, QALY: Quality adjusted life year  
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Records after duplicates removed 
(n = 14510) 
Records screened  
(n = 14510) 
Records excluded  
(n = 14301) 
Full-text articles assessed 
for eligibility  
(n = 209) 
Full-text articles excluded, with 
reasons  
(n = 130) 
- Review papers: 13 
- Conference/Poster abstracts: 61 
- Letter: 7 
- No economic analysis / not 
primary objective: 19 
- AE not reported separately/a 
majority of the sample: 9 
- Clinical quality of life, not utility: 7 
- Foreign Language: 14 
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Figure Click here to download Figure FIGURE 1.doc 
Article Title: The use of decision-analytic models in Atopic Eczema: A systematic review and critical 
appraisal. 
Journal Name: Pharmacoeconomics 
Authors: 
 Miss Emma McManus, MSc 
Norwich Medical School, University of East Anglia, Norwich 
 Prof Tracey Sach*, PhD 
Norwich Medical School, University of East Anglia, Norwich 
 Dr Nick Levell, MD 
Norfolk and Norwich University Hospital, Norwich 
*Corresponding author: 
Name: Prof Tracey Sach 
Email address: t.sach@uea.ac.uk 
Telephone: 01603 59 2022 
 
Supplementary material 1: Data Extraction Table 
General Information 
Review ID  
Author, Year  
Title  
Reviewer  
Date of review  
Publication type  
Population and setting 
Type of study  
Stated type of economic analysis  
Other Click here to download Other SUPPLEMENTARY MATERIAL
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Actual type of economic analysis (if different)  
Country of study  
Study setting  
Population  
Study size  
Method of recruitment  
Recruitment time period  
Inclusion criteria  
Exclusion criteria  
Study design 
Primary intervention  
Secondary intervention(s)  
Comparators  
Time horizon (for follow up)  
Outcomes 
Outcomes measure (1)  
Method of measurement (1)  
Outcome measure (2)  
Method of measurement (2)  
Outcome measure (3)  
Method of measurement (3)  
Secondary outcome measure(s)  
Method of measurement(s)  
For utility studies: what value set or direct method of 
measurement has been used? 
 
Timing of measurements  
Discount rate, outcomes  
Method of dealing with missing data - outcomes  
Resource and Cost information 
Cost perspective  
Intervention costs  
Direct cost items  
Method of capturing direct cost items  
Direct cost data sources  
Indirect cost items  
Method of capturing indirect cost items  
Indirect cost data sources  
Resource items collected  
Resource use, recall period  
Method of dealing with missing data - cost  
Price year  
Currency  
Inflation rate, cost  
Discount rate, cost  
Results 
Resource use and costs  
Reported cost effectiveness  
Appropriateness of ICER  
Sensitivity analysis  
Major Result(s)  
Conclusions  
Funding source  
Model specific information 
Type of decision analytic model  
Model perspective  
Model population  
Cohort or individual?  
Model assumptions  
Model exclusions  
Method for dividing disease severity  
Distinction between body/face eczema?  
Interventions included  
Time horizon  
Cycle length  
Value of any parameters used  
Source of parameters  
Software used for model  
Type of sensitivity analysis performed  
Method of model validation  
Author specified limitations  
 
Philips Criteria 
Dimensions of 
quality 
Questions for critical appraisal Response 
(Yes/No/Partial//NA) 
Comments 
Structure 
Statement of 
decision 
problem / 
objective  
1 Is there a clear statement of the 
decision problem? 
  
2 Is the objective of the evaluation 
and model specified and consistent 
with the stated decision problem? 
  
3 Is the primary decision maker 
specified?   
  
Statement of 
scope / 
perspective  
4 Is the perspective of the model 
stated clearly? 
  
5 Are the model inputs consistent with 
the stated perspective?  
  
6 Has the scope of the model been 
stated and justified? 
  
7 Are the outcomes of the model 
consistent with the perspective, 
scope and overall objective of the 
model? 
  
Rationale for 
structure  
8 Has the evidence regarding the 
model structure been described? 
  
9 Is the structure of the model 
consistent with a coherent theory of 
the health condition under 
evaluation?  
  
10 Have any competing theories 
regarding model structure been 
considered?  
  
11 Are the sources of data used to 
develop the structure of the model 
specified? 
  
12 Are the causal relationships 
described by the model structure 
justified appropriately? 
  
13 Are the structural assumptions 
transparent and justified? 
  
Structural 
assumptions  
14 Are the structural assumptions 
reasonable given the overall 
objective, perspective and scope of 
the model? 
  
Strategies/ 
comparators  
15 Is there a clear definition of the 
options under evaluation? 
  
16 Have all feasible and practical 
options been evaluated? 
  
17 Is there justification for the 
exclusion of feasible options? 
  
Model type  18 Is the chosen model type 
appropriate given the decision 
problem and specified causal 
relationships within the model?  
  
Time horizon  19 Is the time horizon of the model 
sufficient to reflect all important 
differences between options? 
  
20 Is the time horizon of the model, 
and the duration of treatment and 
treatment effect described and 
justified? 
  
21 Has a lifetime horizon been used? If 
not, has a shorter time horizon been 
justified? 
  
Disease states/ 
pathways  
22 Do the disease states (state 
transition model) or the pathways 
(decision tree model) reflect the 
underlying biological process of the 
  
disease in question and the impact 
of interventions? 
Cycle length  23 Is the cycle length defined and 
justified in terms of the natural 
history of disease? 
  
Data 
Data 
identification  
24 Are the data identification methods 
transparent and appropriate given 
the objectives of the model?  
  
25 Where choices have been made 
between data sources, are these 
justified appropriately? 
  
26 Has particular attention been paid to 
identifying data for the important 
parameters in the model? 
  
27 Has the process of selecting key 
parameters been justified and 
systematic methods used to identify 
the most appropriate data? 
  
28 Has the quality of the data been 
assessed appropriately? 
  
29 Where expert opinion has been 
used, are the methods described 
and justified? 
  
Pre-model data  
 
30 Are the pre-model data analysis 
methodology based on justifiable 
  
statistical and epidemiological 
techniques? 
Baseline data  31 Is the choice of baseline data 
described and justified?  
  
32 Are transition probabilities 
calculated appropriately? 
  
33 Has a half cycle correction been 
applied to both cost and outcome? 
  
Treatment 
effects  
 
34 If relative treatment effects have 
been derived from trial data, have 
they been synthesised using 
appropriate techniques? 
  
35 Have the methods and assumptions 
used to extrapolate short-term 
results to final outcomes been 
documented and justified? Have 
alternative assumptions been 
explored through sensitivity 
analysis? 
  
36 Have assumptions regarding the 
continuing effect of treatment once 
treatment is complete been 
documented and justified? Have 
alternative assumptions been 
explored through sensitivity 
analysis? 
  
Quality-of-life 
weights 
(utilities)  
37 Are the utilities incorporated into the 
model appropriate? 
  
38 Is the source for the utility weights 
referenced? 
  
39 Are the methods of derivation for 
the utility weights justified? 
  
Data 
incorporation  
40 Have all data incorporated into the 
model been described and 
referenced in sufficient detail? 
  
41 Has the use of mutually inconsistent 
data been justified (i.e. are 
assumptions and choices 
appropriate)? 
  
42 Is the process of data incorporation 
transparent? 
  
43 If data have been incorporated as 
distributions, has the choice of 
distribution for each parameter been 
described and justified? 
  
Assessment of 
uncertainty 
  
 
44 Have the four principal types of 
uncertainty been addressed? 
  
45 If not, has the omission of particular 
forms of uncertainty been justified?  
  
Methodological 46 Have methodological uncertainties 
been addressed by running 
  
alternative versions of the model 
with different methodological 
assumptions? 
Structural 47 Is there evidence that structural 
uncertainties have been addressed 
via sensitivity analysis? 
  
Heterogeneity 
 
48 Has heterogeneity been dealt with 
by running the model separately for 
different sub-groups? 
  
Parameter 49 Are the methods of assessment of 
parameter uncertainty appropriate? 
  
50 Has probabilistic sensitivity analysis 
been done, if not has this been 
justified? 
  
51 If data are incorporated as point 
estimates, are the ranges used for 
sensitivity analysis stated and 
justified? 
  
Uncertainty and Consistency 
Internal 
consistency  
52 Is there evidence that the 
mathematical logic of the model has 
been tested thoroughly before use? 
  
External 
consistency  
53 Are the conclusions valid given the 
data presented? 
  
54 Are any counterintuitive results from 
the model explained and justified? 
  
55 If the model has been calibrated 
against independent data, have any 
differences been explained and 
justified?  
  
56 Have the results of the model been 
compared with those of previous 
models and any differences in 
results explained? 
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Supplementary material 2: Philips Criteria responses 
Included within the tables below are the responses to the Philips checklist items [8], for each of the studies included within the review, divided 
into structure, data and certainty. The full questions are coded within the data extraction form, provided in Appendix 3. Here, ‘Y’ means yes, 
‘N’ means no or not enough information provided to judge, ‘P’ means partial and ‘N/A’ means not applicable. 
Structure: 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
Abramovits, W. 
(2003) [21] 
Y Y N Y Y Y Y N Y N N Y P Y Y Y N/A Y P P N Y N 
Bhanegaonkar, A. 
(2015) [23] 
Y Y N Y Y Y Y N Y N N Y Y Y Y Y N/A Y Y Y N Y P 
Bhanegaonkar, A. 
(2015) [24] 
Y Y N P N Y Y N Y N N Y Y Y Y Y N/A Y Y Y N Y P 
Bhanegaonkar, 
A.(2014) [25]  
Y Y N Y Y Y Y P Y N Y Y Y Y Y Y N/A Y Y Y N Y P 
Botteman, M. 
(2015) [26] 
Y Y N Y Y Y Y N N N N N N N Y N N Y Y N N N N 
Coyle, D. (2004) 
[32] 
Y Y Y Y Y P Y N Y N Y N N N Y Y N/A P N N N P N 
de Tiedra, A. 
(1997) [29] 
P Y N Y Y N Y N N N N N N N Y Y N/A N N N N P N/A 
Ellis, C. N., et al. 
(2003) [22] 
Y Y N Y Y Y Y Y Y Y N N Y Y Y Y N/A Y P P N Y P 
Ellis, C. N., et al. 
(2006) [33]  
Y Y N Y Y Y Y N Y N N N Y Y Y Y N/A Y N N N Y N 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
Garside, R. (2005) 
[28] 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y P 
Healy, E., et al. 
(2011) [34]  
Y Y Y Y Y Y Y N N N N N N N Y Y N/A N P P Y N N 
Hjalte, F. (2009) 
[35]  
Y Y N Y Y P Y N P N N N P N Y Y Y Y Y Y N N P 
Hjelmgren, J. 
(2007) [36] 
Y Y Y Y Y N Y N Y N Y N N Y Y Y N/A Y P N N Y Y 
Iskedjian, M. 
(2012) [17] 
Y Y Y Y Y Y Y N Y N N N N Y Y Y N/A N Y P N P P 
Iskedjian, M. 
(2010) [18] 
Y Y Y Y Y Y Y N P N Y N N N Y Y N/A N Y P N P P 
Iskedjian M. 
(2012) [19] 
Y Y Y Y Y Y Y N Y N N N N Y Y Y N/A N P P N P N 
Kiencke, P. (2013) 
[30]  
Y Y N N N P Y N P N N Y Y Y Y N N N Y P Y Y N/A 
Lenoir-Wijnkoop, 
I. (2010) [37]  
Y Y Y Y P Y Y Y N Y N N N N Y Y N/A N P N N N P 
Mertens, J. (2012) 
[31]  
Y Y Y Y Y Y Y N Y N Y N Y Y Y Y N/A N Y N N Y N/A 
Norrlid, H. (2016) 
[39] 
Y P N Y Y P Y N Y N N Y Y Y Y N N Y Y P N P N/A 
Pitt, M. (2006) 
[27] 
Y Y Y Y Y Y Y P Y P N Y Y Y Y Y Y Y P Y P Y Y 
Su, J. (2012) [20] Y Y Y Y Y Y Y N Y N N Y Y Y Y Y N/A Y N Y P Y P 
Tang, M. B. Y. 
(2015) [38] 
Y Y N Y Y P Y N Y N N N Y Y Y Y N/A Y N P N Y Y 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
Xu, S. (2016) [40] Y N N N N N N N N N Y N P Y Y N N N N N N P N/A 
 
Data: 
 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 
Abramovits, W. 
(2003) [21] 
N N N N N N P P N N P N P N/A N/A N/A 
Bhanegaonkar, A. 
(2015) [23] 
N N/A N N N N N Y N N N/A N/A Y N/A N/A N/A 
Bhanegaonkar, A. 
(2015) [24] 
N N/A N N N N N Y N N N/A N/A Y Y Y N 
Bhanegaonkar, 
A.(2014) [25]  
N N N N N N N Y N N N/A N/A Y Y Y Y 
Botteman, M. 
(2015) [26] 
N N N N N N N P N N N N/A N N Y N 
Coyle, D. (2004) 
[32] 
P N/A N N N N N N N N N N/A N P Y Y 
de Tiedra, A. 
(1997) [29] 
P N/A N P N P Y Y N/A N/A Y N N N/A N/A N/A 
Ellis, C. N., et al. 
(2003) [22] 
N N/A N Y Y N N P N N Y N/A Y N/A N/A N/A 
Ellis, C. N., et al. 
(2006) [33]  
N N/A N Y N N/A N P N Y N/A N/A N/A Y Y Y 
Garside, R. (2005) 
[28] 
Y Y Y Y Y P Y Y N N Y Y Y Y Y Y 
 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 
Healy, E., et al. 
(2011) [34]  
Y Y N N Y P N Y N N N/A N/A N P N N 
Hjalte, F. (2009) 
[35]  
N N/A N N N N N Y P P N N N/A Y Y N/A 
Hjelmgren, J. 
(2007) [36] 
N N/A P N N N/A N N N N N/A N N/A Y Y Y 
Iskedjian, M. 
(2012) [17] 
Y N N Y Y Y Y Y N N Y P N N/A N/A N/A 
Iskedjian, M. 
(2010) [18] 
Y N/A N Y Y Y Y Y N N Y N N N/A N/A N/A 
Iskedjian M. 
(2012) [19] 
Y N/A N Y Y Y N Y N N Y N N N/A N/A N/A 
Kiencke, P. (2013) 
[30]  
N N/A N P N N/A Y Y Y N/A N/A P N N/A N/A N/A 
Lenoir-Wijnkoop, 
I. (2010) [37]  
P N N N N N N N N N N N N/A N Y N 
Mertens, J. (2012) 
[31]  
N N/A N N P N Y Y N N/A N/A N/A N/A N/A N/A N/A 
Norrlid, H. (2016) 
[39] 
N N/A N N P N/A N N N/A N/A N/A N N Y Y N 
Pitt, M. (2006) [27] Y N Y Y N N N Y N N/A N P Y Y Y N 
Su, J. (2012) [20] Y N/A N Y N P N Y N N Y Y N N/A N/A N/A 
Tang, M. B. Y. 
(2015) [38] 
N P N P N N N Y N N/A N N P N Y N 
Xu, S. (2016) [40] Y N/A N N N N/A N/A N/A N/A N/A N/A N/A N N Y N 
  40 41 42 43 44 45 46 47 48 49 50 51 
Abramovits, W. (2003) [21] N N/A N N/A P N N N N P N P 
Bhanegaonkar, A. (2015) [23] P N/A Y N/A P N P N N Y Y Y 
Bhanegaonkar, A. (2015) [24] P N/A Y P P N Y N N Y Y Y 
Bhanegaonkar, A.(2014) [25]  Y N/A Y P P N Y N N Y Y P 
Botteman, M. (2015) [26] P N/A P N P N Y N N Y Y N 
Coyle, D. (2004) [32] N N/A N N/A P N N Y N Y N Y 
de Tiedra, A. (1997) [29] P N/A Y N/A P N N N N P N N 
Ellis, C. N., et al. (2003) [22] P N/A Y N/A P N N N N Y N P 
Ellis, C. N., et al. (2006) [33]  N N/A P N/A P N N N N Y N N 
Garside, R. (2005) [28] Y N/A Y P P N N N Y Y Y Y 
Healy, E., et al. (2011) [34]  Y N/A Y N/A P N N N Y Y Y Y 
Hjalte, F. (2009) [35]  Y N/A N N/A P N N N N Y N N 
Hjelmgren, J. (2007) [36] P N/A Y N/A P N N N Y P N N 
 40 41 42 43 44 45 46 47 48 49 50 51 
Iskedjian, M. (2012) [17] Y N/A Y P P N P N N Y Y Y 
Iskedjian, M. (2010) [18] Y N/A Y P P N P N N Y Y Y 
Iskedjian M. (2012) [19] Y N/A Y N/A P N N N N Y Y N/A 
Kiencke, P. (2013) [30]  P N/A P N/A P N N N N P N P 
Lenoir-Wijnkoop, I. (2010) [37]  P N/A P N/A P N N N N N N N 
Mertens, J. (2012) [31]  P N/A P N/A P N N N N P N N 
Norrlid, H. (2016) [39] N N/A Y P P N P N N N N Y 
Pitt, M. (2006) [27] N N/A P Y P N N N Y Y Y Y 
Su, J. (2012) [20] Y N/A Y N/A P N Y N N Y Y Y 
Tang, M. B. Y. (2015) [38] Y N/A Y N/A P N Y N N Y N P 
Xu, S. (2016) [40] Y N/A Y N/A P N N N N Y N Y 
 
Certainty: 
 52 53 54 55 56 
Abramovits, W. (2003) [21] N Y N/A N/A N 
Bhanegaonkar, A. (2015) [23] N Y Y N/A N 
Bhanegaonkar, A. (2015) [24] N Y N/A N/A P 
Bhanegaonkar, A.(2014) [25]  N Y N/A N/A Y 
Botteman, M. (2015) [26] N Y N/A N/A Y 
Coyle, D. (2004) [32] N Y N/A N/A N 
de Tiedra, A. (1997) [29] N Y N/A N/A N 
Ellis, C. N., et al. (2003) [22] N Y N/A N/A N 
Ellis, C. N., et al. (2006) [33]  N Y N/A N/A N 
Garside, R. (2005) [28] N Y N/A Y Y 
Healy, E., et al. (2011) [34]  N Y N/A N/A P 
Hjalte, F. (2009) [35]  N Y N/A N/A N 
Hjelmgren, J. (2007) [36] N Y N/A N/A N 
Iskedjian, M. (2012) [17] N Y N/A N/A N 
 52 53 54 55 56 
Iskedjian, M. (2010) [18] N Y N/A N/A N 
Iskedjian M. (2012) [19] N Y N/A N/A N 
Kiencke, P. (2013) [30]  N/A Y N/A N/A N 
Lenoir-Wijnkoop, I. (2010) [37]  N P N/A N/A N 
Mertens, J. (2012) [31]  N Y N/A N/A P 
Norrlid, H. (2016) [39] N Y N/A N/A Y 
Pitt, M. (2006) [27] N Y N/A N/A N 
Su, J. (2012) [20] N Y N/A N/A N 
Tang, M. B. Y. (2015) [38] N Y N/A N/A N 
Xu, S. (2016) [40] N/A Y N/A N/A N 
 
 
